Skin Analytics Secures £15 Million for AI Cancer Detection
In a significant stride toward revolutionizing skin cancer detection, Skin Analytics, a pioneering British healthtech company, has secured an impressive £15 million in Series B funding led by the esteemed Intrepid Growth Partners. This investment not only underscores the company’s mission to eradicate skin cancer but also highlights the vital role of innovative technology in healthcare. With its groundbreaking AI-powered device, DERM, Skin Analytics is poised to reshape the dermatology landscape, particularly in markets severely impacted by a shortage of specialists.
The recent achievement of a Class III CE mark for DERM marks a pivotal moment for Skin Analytics, as it becomes the world's first legally authorized AI medical device capable of independently making clinical decisions on skin cancer.
Demonstrating an astounding 99.8% accuracy in ruling out skin cancer—outperforming traditional dermatologists' accuracy of 98.9%—DERM has already transformed dermatological care within the NHS. Deployed in 26 NHS sites, it has facilitated over 150,000 patient interactions and detected more than 14,000 cases of cancer, significantly reducing unnecessary face-to-face appointments.
As healthcare systems globally strive to keep pace with rising patient demands and a dwindling number of dermatologists—averaging only 30 specialists per 1 million population in Europe—the investment from Intrepid Growth Partners comes at a critical time. Neil Daly, the visionary founder and CEO of Skin Analytics, envisions a future where **AI not only alleviates specialist scarcity but democratizes access to vital skin health services**. With plans to expand internationally to underserved markets like Europe and Australia, as well as accelerating entry into the U.S. market, Skin Analytics is laying the groundwork for groundbreaking healthcare advancements that could save countless lives. This funding represents only the beginning of a global movement harnessing machine intelligence to redefine cancer detection and patient care.
Key Terms Explained
- Series B funding
- This is typically the second round of funding for a startup company by private equity investors or venture capitalists. It's intended to take the company to the next level, beyond the initial development stage.
- AI-powered device
- A type of technology that mimics human intelligence to perform tasks, like learning from experiences, recognizing patterns, and making decisions, with algorithms it is capable of processing and analyzing information.
- Class III CE mark
- This is a certification mark that indicates conformity with European health, safety, and environmental protection standards for products. Class III represents the devices with the highest risk potential.
Frequently Asked Questions
- How much funding has Skin Analytics secured in its Series B round?-Skin Analytics has secured £15 million in its Series B funding round.
- Who led the recent investment in Skin Analytics?+
- What is the significance of Skin Analytics getting a Class III CE mark for its AI device, DERM?+
- What is the accuracy rate of DERM in ruling out skin cancer?+
- What are Skin Analytics' future plans following their recent funding?+
They've invested in Skin Analytics
Get to know these Healthtech investors
Click here for a full list of 7,526+ startup investors in the UK